GH Research (GHRS) Change in Acquisitions & Divestments (2024 - 2025)

GH Research's (GHRS) quarterly Change in Acquisitions & Divestments came in at $8.9 million in Q4 2025, up 6.02% year-on-year from $8.4 million in Q4 2024, and down 9.81% quarter-over-quarter from $9.8 million in Q3 2025.

GH Research (GHRS) Change in Acquisitions & Divestments (2024 - 2025) Analysis & Trends

GH Research's Change in Acquisitions & Divestments history runs 2 years deep, the most recent figure standing at $8.9 million for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments rose 6.02% year-over-year to $8.9 million in Q4 2025; TTM through Dec 2025 was $26.7 million, a 1.75% decrease from a year earlier, with the FY2025 full-year figure at $26.7 million, down 1.75% from the prior year.
  • Change in Acquisitions & Divestments fell to $8.9 million in Q4 2025 per GHRS's latest filing, from $9.8 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $9.8 million in Q3 2025 and bottomed at $3.2 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,200.25 Bn 66,199.96 Bn -
2 Nanobiotix 1,908.00 Bn 1,907.94 Bn -
3 Akari Therapeutics 959.56 Bn 959.56 Bn -
4 BeOne Medicines 471.75 Bn 466.96 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.94 Bn 114.69 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.87 Bn 61.12 Bn 3.31 Bn
7 Belite Bio 62.43 Bn 62.43 Bn -
8 Argenx Se 55.86 Bn 50.68 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.49 Bn 34.48 Bn 959.66 Mn
10 GH Research 1.72 Bn 1.48 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2025 8.86 Mn
Dec 31, 2025 8.86 Mn
Sep 30, 2025 9.82 Mn
Sep 30, 2025 9.82 Mn
Jun 30, 2025 3.18 Mn
Jun 30, 2025 3.18 Mn
Mar 31, 2025 4.84 Mn
Mar 31, 2025 4.84 Mn
Dec 31, 2024 8.36 Mn
Dec 31, 2024 8.36 Mn
Sep 30, 2024 5.29 Mn
Sep 30, 2024 5.29 Mn
Jun 30, 2024 9.74 Mn
Jun 30, 2024 9.74 Mn
Mar 31, 2024 3.80 Mn
Mar 31, 2024 3.80 Mn